D-Wave Quantum: A 94.31% Simulation Score, a Securities Suit and a $27 Target Collide Before November 10

D-Wave Quantum's stock has been taking its cues from the wider market rather than from its own news flow. The shares fell 11% in a broad selloff that swept through technology and AI-related names, with media reports linking the drop to sector-wide pressure rather than any fresh company announcement. AP reported heavy selling across AI-adjacent businesses and chip stocks, and the losses in semiconductors spilled over into quantum computing peers — Rigetti Computing and IonQ both came under pressure alongside D-Wave.

The retreat extends a rough stretch for the name, which had already lost 13% in the prior session. Analysts have been adjusting their models to the weaker backdrop. On Monday, Craig Ellis of B. Riley Securities cut his price target on D-Wave to $27 from $40, keeping his buy rating intact and pointing to softness across the quantum computing and AI sector as the reason.

A Lawsuit, a Deadline and a Disputed Record

Company-specific news has added its own weight. Pomerantz disclosed on October 29 that a securities class action had been filed against D-Wave and certain executives, alleging misleading statements about the business and its revenue prospects. The claims are unproven. The notice sets December 15, 2026 as the deadline for motions to be appointed lead plaintiff.

Against that legal backdrop, the operating story has continued to produce headlines — most of them from the laboratory rather than the income statement.

Medical Research as the Proving Ground

On Monday, D-Wave reported on work by researchers at Florida Atlantic University, who used its annealing hardware to predict lung cancer from a limited data set. According to the company, the annealing-based method reached 94.31% accuracy in simulation and 91.90% on quantum hardware. The results are preliminary, and the researchers augmented their data set with additional samples, including synthetic ones.

That combination is what makes the project worth watching — and worth treating with caution. The study attacks a concrete medical task, which argues for the technology being tested against real-world problems. But the limited, artificially expanded data set means its evidential weight should not be overstated. How much economic value the approach ultimately carries depends on how robustly it develops from here.

A second signal arrived on October 28 from drug discovery. According to D-Wave, customer Shionogi took first place in the quality-of-life category of the NEDO Challenge with its quantum computing research. The company put the prize money at ¥40 million.

The award raises the visibility of a specific customer project. For D-Wave's valuation, it gains weight mainly if such research approaches prove themselves in sustained use. What ties both announcements together is the work on a clearly defined problem: drug discovery on one side, medical prediction on the other.

From Technical Possibility to Usable Solution

Those examples mark the transition on which quantum computing must now be judged — from technical possibility to usable problem-solving. D-Wave's announcements offer different entry points into that task, with research, software improvements and training each addressing a separate part of it.

This week the company reported upgrades to Stride, its hybrid optimization solver. In benchmark tests balancing assembly lines, the new version found better solutions in 15 seconds than the previous version managed in 120 seconds, according to the company. In parallel, D-Wave launched a learning path with three courses on applied quantum optimization.

The interplay matters here: a more capable tool can make application easier, provided users know how to put it to work on their problems. The training offering addresses that practical side, while the benchmark gives the performance claim a concrete reference point. How much that claim counts for investors depends on how relevant such improvements prove in actual deployment.

October's collaboration with LG CNS fits the same pattern. The non-binding letter of intent is meant to advance the use of quantum computing for enterprise optimization in South Korea and international markets. Its potential value lies in broader adoption — if the intent turns into concrete cooperation.

The Financial Yardstick Comes Next

The next scheduled financial checkpoint is the third-quarter 2026 results, which D-Wave will publish before the market opens on November 10, 2026.

Technical progress and financial development belong together in any assessment. Customer research, better tools and training all point to work on practical use; a durable economic outlook emerges only if that use shows up in the business. D-Wave's most telling story is therefore the link between technology and application — and the medical projects make that link tangible. It becomes more convincing for investors when solid research results and economic progress point in the same direction.